Innophos Holdings, Inc. (IPHS) Expected to Post Earnings of $0.51 Per Share

Analysts expect Innophos Holdings, Inc. (NASDAQ:IPHS) to announce earnings of $0.51 per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Innophos’ earnings. Innophos posted earnings of $0.52 per share in the same quarter last year, which would suggest a negative year over year growth rate of 1.9%. The firm is expected to report its next earnings report before the market opens on Wednesday, February 20th.

On average, analysts expect that Innophos will report full-year earnings of $2.25 per share for the current financial year. For the next financial year, analysts expect that the firm will post earnings of $2.50 per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Innophos.

Several analysts recently commented on IPHS shares. BidaskClub lowered shares of Innophos from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Zacks Investment Research lowered shares of Innophos from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 25th. Finally, ValuEngine raised shares of Innophos from a “strong sell” rating to a “sell” rating in a research note on Monday, February 4th.

A number of hedge funds have recently added to or reduced their stakes in IPHS. Deprince Race & Zollo Inc. lifted its stake in Innophos by 40.7% during the fourth quarter. Deprince Race & Zollo Inc. now owns 612,289 shares of the specialty chemicals company’s stock valued at $15,019,000 after purchasing an additional 177,149 shares during the last quarter. Northpointe Capital LLC lifted its stake in Innophos by 2,069.0% during the third quarter. Northpointe Capital LLC now owns 169,140 shares of the specialty chemicals company’s stock valued at $7,510,000 after purchasing an additional 161,342 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Innophos during the fourth quarter valued at approximately $3,847,000. BlackRock Inc. lifted its stake in Innophos by 5.1% during the third quarter. BlackRock Inc. now owns 2,800,584 shares of the specialty chemicals company’s stock valued at $124,346,000 after purchasing an additional 134,916 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in Innophos by 15.8% during the third quarter. American Century Companies Inc. now owns 726,190 shares of the specialty chemicals company’s stock valued at $32,243,000 after purchasing an additional 99,315 shares during the last quarter. 93.11% of the stock is owned by institutional investors and hedge funds.

Shares of Innophos stock traded up $0.17 on Monday, hitting $30.56. The company had a trading volume of 87,600 shares, compared to its average volume of 109,756. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.79 and a quick ratio of 1.36. The stock has a market capitalization of $596.14 million, a PE ratio of 12.42 and a beta of 1.38. Innophos has a 52 week low of $22.57 and a 52 week high of $50.40.

About Innophos

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

See Also: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply